 |
|
Acumen Pharmaceuticals
South San
Francisco, CA
|
Acumen is pioneering
ADDL neurobiology, the causative
agent in Alzheimer's disease, and
has a fundamental patent estate on
this target. Acumen has a license
agreement and R&D collaboration
with Merck.
www.acumenpharm.com |
Arcturus
Mountain View, CA
|
Arcturus is the industry leader in Laser Capture Microdissection
(LCM) and reagent systems for microgenomics, the molecular
analysis of microscopic tissue samples. The assets of the company were recently acquired by AviarDx and Molecular Devices.
www.arctur.com |
Anesiva (formerly known as Corgentech)
South San Francisco, CA
|
Anesiva (fka Corgentech) is a biopharmaceutical company focused on the development and
commercialization of DNA-based novel therapeutics for unmet needs in inflammatory diseases, infectious diseases
and cancer.
www.anesiva.com |
CyDex, Inc.
Lenaxa, KS
|
CyDex,
Inc. is a specialty pharmaceutical
company developing a pipeline of
promising new pharmaceutical products
with advanced drug delivery technologies,
based on CAPTISOL® , a modified
cyclodextrin that can significantly
improve the solubility and stability
of drugs.
www.cydexinc.com |
Dow Pharmaceutical Sciences
Petaluma, CA
|
Dow Pharmaceutical Sciences develops
topical products for
pharmaceutical and biotech clients. Services include formulation
development, penetration studies, analytical, stability, clinical
manufacturing, labeling, FDA submissions, non-clinical and clinical
trials in the US and Europe.
www.dowpharmsci.com |
|
Genomic Health
Redwood City, CA
|
Genomic Health, Inc. (Nasdaq: GHDX) is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched its first test, Oncotype DX(TM), which has been shown to predict the likelihood of breast cancer recurrence and the likelihood of chemotherapy benefit in a large portion of early-stage breast cancer patients.
www.genomichealth.com
|
GlobeImmune Inc.
Louisville, CO
|
GlobeImmune is a biopharmaceutical company pioneering the discovery, development and manufacturing of potent, targeted molecular immunotherapies called Tarmogens for the treatment of infectious diseases and cancer.
www.globeimmune.com
|
Medisyn Technologies, Inc.
Minnetonka, MN
|
Medisyn
Technologies is a unique small molecule
design company that uses proprietary
technology to make drug discovery faster,
more predictable and less expensive.
Based
on molecular topology, Medisyn's Fast
Forward Engineering(tm) platform enables
the design of novel, diverse and unexpected
compounds.
www.medisyntech.com |
Metabasis Therapeutics, Inc.
San Diego, CA
|
Metabasis Therapeutics is a biopharmaceutical company
focused on the discovery, development and commercialization of novel small molecule drugs
principally to treat liver diseases and metabolic diseases linked to pathways in the liver.
Metabasis has a broad product pipeline targeting large markets with significant unmet medical needs.
www.mbasis.com
|
Neurotech Pharmaceuticals, Inc.
Lincoln, RI
|
Neurotech is developing recombinant cell technology for the treatment of chronic retinal diseases. The company’s Encapsulated Cell Technology (ECT) platform enables long-term, sustained delivery of therapeutic factors to the back of the eye.
www.neurotechusa.com
|
|
Osteogenix Incorporated
Palo Alto, CA |
Osteogenix is a therapeutic products company with novel products for the large and rapidly growing area of bone repair and bone growth. Osteogenix was founded in 2005 to clinically develop and commercialize the osteo-pharmacologic platform discovered and patented by Dr. Mundy and his associates.
www.osteogenix.com
|
Prolacta Bioscience Inc.
Monrovia, CA
|
Prolacta Bioscience™ is a life sciences company specializing in human milk formulations for use in the NICU. With the ground-breaking development of the first commercially available Human Milk Fortifier made from human milk. Prolacta® is dedicated to improving the outcome of neonatal care.
www.prolacta.com
|
Quidel Corporation
San Diego, CA
|
Quidel Corporation serves to enhance the health and well being of people around the globe through the discovery, development, manufacturing and marketing of rapid diagnostic solutions at the point of care (POC) in infectious diseases and reproductive health. Quidel's Specialty Products Group (SPG) develops research products in the fields of oncology and bone health with future point-of-care applications.
www.quidel.com |
Revance Therapeutics, Inc
Mountain View, CA
|
Revance Therapeutics, Inc. is a
clinical-stage specialty biopharmaceutical
company devoted to creating the next generation of therapeutic
and aesthetic
dermatology. The company's current product pipeline consists
of development
programs in hyperhidrosis, regeneration of elastin, and regression
of fat
and cellulite.
www.revance.com |
RiverVest Venture Partners
St. Louis, MO |
RiverVest
Venture Partners is a venture capital
firm investing in the most promising
life science companies nationwide.
www.rivervest.com |
Singulex, Inc.
St. Louis, MO |
Singulex, Inc. is a bioanalytical company that develops state-of-the-art integrated systems for detecting and counting individual molecules. Singulex is applying its technology and products to low abundance proteomics monitoring, which includes biomarker validation, implementation, and clinical diagnostics.
www.singulex.com |
Takeda Research Investment, Inc. (TRI)
Palo Alto, CA |
TRI is the corporate venture arm of Takeda Pharmaceutical Company Limited, a world-class pharmaceutical company and the largest in Japan. A wholly-owned subsidiary of Takeda America Holdings, Inc., TRI started operations in 2002. Our aim is to encourage and support therapeutic innovation in biopharmaceutical companies and academic centers of excellence, through early stage capital investment and provision of access to the resources of a multinational pharmaceutical company.
www.tri-takeda.com
|
XDx, Inc.
Brisbane, CA
|
XDx is a molecular diagnostics company focused on the discovery, development and commer-cialization of noninvasive gene expression-based tests for the monitoring of transplant rejection and autoimmune diseases. Their first test, AlloMap® molecular expression testing, was launched in 2005 and when used in conjunction with clinical judgment and assessment of heart graft function, it can help identify heart transplant patients who are at a very low risk of acute cellular rejection.
www.xdx.com
|
